End Medical, Inc., a secretly held restorative gadget organization which grows negligibly obtrusive, uterine saving answers for ladies who experience the ill effects of symptomatic fibroids, today declared five digests on the Acessa System will be exhibited orally at the 45th Annual Global Congress on Minimally Invasive Gynecology Meeting, being held November 14-18 in Orlando, Florida.
New Instrumentation or Technology on November 16, 2016 from 12:10 PM - 12:48 PM
Dr. Nicole Williams, Gynecology Institute of Chicago, will exhibit two digests on post-showcase results and ultrasound assessments after radiofrequency removal of symptomatic uterine fibroids
Dr. Keith Isaacson, Director of Minimally Invasive Gynecology at Newton-Wellesley, will show clinical results at three years from the LUSTOR Study, a randomized controlled clinical trial of Acessa versus Myomectomy
Dr. Kelly Braun, Associate Professor Augusta University, will introduce on ten specialists' initial understanding and capability utilizing the original Acessa System in only two to five techniques
New Instrumentation or Technology on November 17, 2016 from 2:47 PM - 2:53 PM
Dr. Bruce Lee, creator of the Acessa System, will show on the protected and powerful utilization of radiofrequency removal of uterine fibroids in symptomatic patients with uteri 15-weeks gestational size and more prominent
Dr. Nicole Williams at the Gynecology Institute of Chicago expressed, "I have treated well more than 100 patients with Acessa and have been extremely happy with the outcomes. Similarly essential, Acessa has given the patients in my work on confronting hysterectomy an option. Much of the time, there is no compelling reason to expel the uterus. Acessa permits me to treat the hidden issue (the fibroids), while leaving a generally sound organ unharmed." This week, Dr. Williams will share genuine, post-agent results after the treatment of 81 ladies with symptomatic fibroids.
What are uterine fibroids?
Uterine fibroids are kindhearted, strong tumors in a lady's uterus that can bring about substantial dying, excruciating periods, weight, and distension of the guts [1]. No less than 70% of ladies in the U.S. will create fibroids by the age of 50, with the commonness significantly higher among African-American ladies [2]. Accordingly, they remain a noteworthy ladies' medical problem with huge monetary and conceptive effect. The NIH has discovered that immediate human services costs for the surgical treatment of fibroids are more than $2.1 billion every year [3]. In an across the country inpatient test, over a large portion of a million ladies experienced hysterectomy for generous gynecologic conditions [4] and the American Congress of Obstetricians and Gynecologists (ACOG) states that 39% of all hysterectomies are because of fibroids [5]. After some time, patients and gynecologists are swinging to less obtrusive methodology, and laparoscopic choices are turning out to be more well known [6].
The Acessa System is an insignificantly obtrusive, uterine saving, laparoscopic strategy that conveys radiofrequency vitality to crush the fibroids. After treatment, the fibroid is reabsorbed by the encompassing tissue. The strategy permits the specialist to treat just the fibroids, while saving ordinary capacity of the uterus. Patients commonly go home that day with insignificant distress, and appreciate a fast come back to typical exercises.
About Halt Medical, Inc. – The Company is centered around setting up another standard of tend to ladies with symptomatic uterine fibroids. The Acessa System is cleared by the FDA and has CE stamp for use in percutaneous, laparoscopic coagulation and removal of delicate tissue, including treatment of symptomatic uterine fibroids under laparoscopic ultrasound direction. The Company is situated in Brentwood, CA. For data about the Acessa System, please visit www.acessaprocedure.com.
REFERENCES:
1. www.womenshealth.gov
2. Baird DD et al. High Cumulative Incidence of Uterine Leiomyoma in Black and White Women: Ultrasound Evidence. Am J Obstet Gynecol 2003; 188 (1):100-107.
3. National Institutes of Health reality sheet: http://report.nih.gov/nihfactsheets/viewfactsheet.aspx?csid=50
4. Jacoby VL, Autry A, Jacobson G, Domush R, Nakagawa S, Jacoby A. Across the nation Use of Laparoscopic Hysterectomy Compared with Abdominal and Vaginal Approaches. Obstet Gynecol 2009;114(5):1041-1048.
5. www.ACOG.org. 2011 Women's Health Stats and Facts: p.18.
6. Twijnstra AR, Kolkman W, Trimbos-Kemper GC, Jansen FW. Execution of Advanced Laparoscopic Surgery in Gynecology: National Overview of Trends. J Minim Invasive Gynecol 2010;17(4):487-492.
New Instrumentation or Technology on November 16, 2016 from 12:10 PM - 12:48 PM
Dr. Nicole Williams, Gynecology Institute of Chicago, will exhibit two digests on post-showcase results and ultrasound assessments after radiofrequency removal of symptomatic uterine fibroids
Dr. Keith Isaacson, Director of Minimally Invasive Gynecology at Newton-Wellesley, will show clinical results at three years from the LUSTOR Study, a randomized controlled clinical trial of Acessa versus Myomectomy
Dr. Kelly Braun, Associate Professor Augusta University, will introduce on ten specialists' initial understanding and capability utilizing the original Acessa System in only two to five techniques
New Instrumentation or Technology on November 17, 2016 from 2:47 PM - 2:53 PM
Dr. Bruce Lee, creator of the Acessa System, will show on the protected and powerful utilization of radiofrequency removal of uterine fibroids in symptomatic patients with uteri 15-weeks gestational size and more prominent
Dr. Nicole Williams at the Gynecology Institute of Chicago expressed, "I have treated well more than 100 patients with Acessa and have been extremely happy with the outcomes. Similarly essential, Acessa has given the patients in my work on confronting hysterectomy an option. Much of the time, there is no compelling reason to expel the uterus. Acessa permits me to treat the hidden issue (the fibroids), while leaving a generally sound organ unharmed." This week, Dr. Williams will share genuine, post-agent results after the treatment of 81 ladies with symptomatic fibroids.
What are uterine fibroids?
Uterine fibroids are kindhearted, strong tumors in a lady's uterus that can bring about substantial dying, excruciating periods, weight, and distension of the guts [1]. No less than 70% of ladies in the U.S. will create fibroids by the age of 50, with the commonness significantly higher among African-American ladies [2]. Accordingly, they remain a noteworthy ladies' medical problem with huge monetary and conceptive effect. The NIH has discovered that immediate human services costs for the surgical treatment of fibroids are more than $2.1 billion every year [3]. In an across the country inpatient test, over a large portion of a million ladies experienced hysterectomy for generous gynecologic conditions [4] and the American Congress of Obstetricians and Gynecologists (ACOG) states that 39% of all hysterectomies are because of fibroids [5]. After some time, patients and gynecologists are swinging to less obtrusive methodology, and laparoscopic choices are turning out to be more well known [6].
The Acessa System is an insignificantly obtrusive, uterine saving, laparoscopic strategy that conveys radiofrequency vitality to crush the fibroids. After treatment, the fibroid is reabsorbed by the encompassing tissue. The strategy permits the specialist to treat just the fibroids, while saving ordinary capacity of the uterus. Patients commonly go home that day with insignificant distress, and appreciate a fast come back to typical exercises.
About Halt Medical, Inc. – The Company is centered around setting up another standard of tend to ladies with symptomatic uterine fibroids. The Acessa System is cleared by the FDA and has CE stamp for use in percutaneous, laparoscopic coagulation and removal of delicate tissue, including treatment of symptomatic uterine fibroids under laparoscopic ultrasound direction. The Company is situated in Brentwood, CA. For data about the Acessa System, please visit www.acessaprocedure.com.
REFERENCES:
1. www.womenshealth.gov
2. Baird DD et al. High Cumulative Incidence of Uterine Leiomyoma in Black and White Women: Ultrasound Evidence. Am J Obstet Gynecol 2003; 188 (1):100-107.
3. National Institutes of Health reality sheet: http://report.nih.gov/nihfactsheets/viewfactsheet.aspx?csid=50
4. Jacoby VL, Autry A, Jacobson G, Domush R, Nakagawa S, Jacoby A. Across the nation Use of Laparoscopic Hysterectomy Compared with Abdominal and Vaginal Approaches. Obstet Gynecol 2009;114(5):1041-1048.
5. www.ACOG.org. 2011 Women's Health Stats and Facts: p.18.
6. Twijnstra AR, Kolkman W, Trimbos-Kemper GC, Jansen FW. Execution of Advanced Laparoscopic Surgery in Gynecology: National Overview of Trends. J Minim Invasive Gynecol 2010;17(4):487-492.
No comments:
Post a Comment
Note: only a member of this blog may post a comment.